Cargando…

An update of antispike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies

The use of monoclonal antibodies has expanded beyond the realm of autoimmune disease and cancer therapeutics to communicable diseases. Their antiviral activities were evaluated in some diseases such as SARS MERS (Middle East Respiratory Syndrome) and Ebola. In recent times, antispike SARS-CoV-2 mono...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chatterjee, Suparna, Choudhury, Shouvik, Das, Debaleena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012417/ https://www.ncbi.nlm.nih.gov/pubmed/35343208 http://dx.doi.org/10.4103/ijp.ijp_519_21

Ejemplares similares

Association of Neutralizing Antispike Monoclonal Antibody Treatment With Coronavirus Disease 2019 Hospitalization and Assessment of the Monoclonal Antibody Screening Score
por: Johnson, Patrick W., et al.
Publicado: (2023)

Outcomes of B-Cell-Depleted Patients With Coronavirus Disease 2019 Treated With Antispike Monoclonal Antibodies
por: Yetmar, Zachary A, et al.
Publicado: (2022)

Clinical Prioritization of Antispike Monoclonal Antibody Treatment of Mild to Moderate COVID-19
por: Razonable, Raymund R., et al.
Publicado: (2022)

A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19: The Mayo Clinic Model
por: Razonable, Raymund R., et al.
Publicado: (2021)

Assessment of the levels of antispike SARS-CoV-2 IgG antibodies and their association with clinical characteristics in cohort of patients in Saudi Arabia
por: AlGannas, Nayef S., et al.
Publicado: (2022)

Association of Lower Antispike Antibody Levels with Mortality in ICU Patients with COVID-19 Disease
por: Yelle, Sangeeta, et al.
Publicado: (2023)

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Update
por: Pal, Mahendra, et al.
Publicado: (2020)

519. Risk Factor Analysis for Hospital Admission Following Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Monoclonal Antibody Treatment
por: Abusalem, Lana, et al.
Publicado: (2021)

Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies
por: Ling, Zhiyang, et al.
Publicado: (2022)

Transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to animals: an updated review
por: Salajegheh Tazerji, Sina, et al.
Publicado: (2020)

Antispike Immunoglobulin-G (IgG) Titer Response of SARS-CoV-2 mRNA-Vaccine (BNT162b2): A Monitoring Study on Healthcare Workers
por: Inchingolo, Alessio Danilo, et al.
Publicado: (2022)

Impact of social media on academic performance and interpersonal relation: A cross-sectional study among students at a tertiary medical center in East India
por: Lahiry, Sandeep, et al.
Publicado: (2019)

Past, Present, and Future of Remdesivir: An Overview of the Antiviral in Recent Times
por: Choudhury, Shouvik, et al.
Publicado: (2020)

Acute cardiogenic shock with paclitaxel use in a lung carcinoma patient
por: Choudhury, Shouvik, et al.
Publicado: (2019)

The National Guidelines for Stem Cell Research (2017): What academicians need to know?
por: Lahiry, Sandeep, et al.
Publicado: (2019)

Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: A global health emergency
por: Acter, Thamina, et al.
Publicado: (2020)

Mapping monoclonal anti-SARS-CoV-2 antibody repertoires against diverse coronavirus antigens
por: de Souza, Matheus Oliveira, et al.
Publicado: (2022)

Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Combination Therapy in Patients With Coronavirus Disease 2019 and Primary Antibody Deficiency
por: Pulvirenti, Federica, et al.
Publicado: (2021)

CGRP-monoclonal antibodies and SARS-CoV-2 vaccination
por: Schiano di Cola, Francesca, et al.
Publicado: (2022)

Functionality of Monoclonal Antibody Therapy in SARS-CoV-2
por: Ali, Ruhma, et al.
Publicado: (2022)

Monoclonal antibody therapies against SARS-CoV-2
por: Focosi, Daniele, et al.
Publicado: (2022)

Monoclonal Antibodies to S and N SARS-CoV-2 Proteins as Probes to Assess Structural and Antigenic Properties of Coronaviruses
por: Kumar, Rinki, et al.
Publicado: (2021)

553. Outcomes in Patients Positive for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection After Treatment with Monoclonal Antibody Therapy (MAT) in the Outpatient Setting
por: Nichols, Courtney, et al.
Publicado: (2021)

Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Infusions in High-Risk Outpatients
por: Piccicacco, Nicholas, et al.
Publicado: (2021)

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Associated Urogenital Disease: A Current Update
por: Chu, Guangdi, et al.
Publicado: (2021)

Seroprevalence of antibodies against severe acute respiratory coronavirus 2 (SARS-CoV-2) in household dogs in Japan
por: ITO, Genta, et al.
Publicado: (2021)

Are monoclonal antibodies effective in patients with severe obesity in SARS‐CoV‐2 infected?
por: Ucciferri, Claudio, et al.
Publicado: (2023)

Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy
por: Ragonnet-Cronin, Manon, et al.
Publicado: (2023)

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
por: O’Leary, Valerie Bríd, et al.
Publicado: (2020)

Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus (SARS-CoV)
por: Lai, Szu-Chia, et al.
Publicado: (2005)

Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus
por: Berry, Jody D, et al.
Publicado: (2004)

Establishment and Characterization of Monoclonal Antibodies Against SARS Coronavirus
por: Ohnishi, Kazuo
Publicado: (2007)

535. Comparison of Outcomes in Patients Positive for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection After Monoclonal Antibody Therapy (MAT) with Bamlamivimab or Casirivimab-Imdevimab
por: Nichols, Courtney, et al.
Publicado: (2021)

Time Course of Antispike Antibody Titer after Administration of BNT162b2 mRNA COVID-19 Vaccine in a Patient with Rheumatoid Arthritis on Methotrexate
por: Shinohara, Satoshi, et al.
Publicado: (2023)

Development of SARS-CoV-2 Nucleocapsid Specific Monoclonal Antibodies
por: Terry, James S., et al.
Publicado: (2020)

Development of Monoclonal Antibodies to Detect for SARS-CoV-2 Proteins
por: Mishra, Nawneet, et al.
Publicado: (2022)

SARS-CoV-2 Monoclonal Antibodies in Children: Ethical Considerations
por: Wolfe, Ian D., et al.
Publicado: (2021)

Collection of Monoclonal Antibodies Targeting SARS-CoV-2 Proteins
por: Pribanić Matešić, Marina, et al.
Publicado: (2022)

Monoclonal antibodies binding data for SARS-CoV-2 proteins
por: Mishra, Nawneet, et al.
Publicado: (2022)

Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2
por: Xie, Jiajia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_t0c1jptoo0jsblfec9db8dim4f